ONCO Prime
ONCO Prime is a proprietary dicovery platform focused on identifying novel synthetic lethality targets by using both (a) engineered, isogenic tumor models and (b) patient-derived tumor cells. Ryvu’s OncoPrime platform has broad potential to discover novel synthetic lethal targets across a variety of tumor types. Initial data were presented in colorectal cancer and additional tumors are currently being explored.
Key highlights
Ryvu’s ONCO Prime platform has broad potential to discover novel synthetic lethal targets across a variety of tumor types. Ryvu’s approach allows exploring novel treatment strategies via phenotypic screening in two ways: (a) engineered, isogenic tumor models and (b) patient-derived tumor cell models.
ONCO Prime has already identified several novel targets for KRAS-driven tumors, and additional tumor models are currently being explored.
ONCO Prime is co-financed by the European Union under the Operational Programme European Funds for Modern Economy 2021-2027. Project title: “ONCO Prime: new possibilities for personalised anti-cancer therapy based on patient-derived primary cell cultures, omics characterisation, and functional assays”. Grant Agreement no: FENG.01.01-IP.02-0095/23.
Ryvu Technology
program
indication
discovery
PRECLINICAL
PHASE I
PHASE II
partner
program
ONCO Prime – Precision Medicine
indication
Oncology
discovery
PRECLINICAL
PHASE I
PHASE II
Contact
FOR MEDICAL PROFFESIONALS & INVESTIGATORS
If you are a medical professional, an investigator for a RYVU trial, or would like information about becoming an investigator, please contact us at [email protected] or use contact form.
